warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
The purpose of this study is to evaluate the efficacy of duloxetine 30/60 mg once daily (QD) compared with placebo on the reduction of average pain severity during a 13-week, double-blind treatment phase in adolescents (aged 13 to 17 years) with Juvenille Primary Fibromyalgia Syndrome.
Who may be Eligible  
Male or female aged 13 to 17 with a diagnosis of Juvenille Primary Fibromyalgia Syndrome.
Speciality/Disorder  
Fibromyalgia
IRB Number  
CHS1-11-074
Principal Investigator  
Tcheremissine, Oleg

For More Information, Contact  Dineen  , Gardner
Phone:  (704) 446-7511  Fax:  (704) 446-7505  
Email:  dineen.gardner@carolinashealthcare.org
Address:465 North Wendover Road Charlotte, NC 28211
Close